Dare Bioscience, Inc.

SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience, is scheduled to present at Stifel's 2026 Healthcare Conference happening November 10 – 12, 2026 in New York, New York.

Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development

Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience's growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs in women's health

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women's health needs, including for women affected by breast cancer The program addresses non-hormonal approaches to women's sexual health which aligns with Daré Bioscience's innovation strategy and development of proprietary Sildenafil Cream, 3.6% Daré Bioscience will also present research on Sildenafil Cream, 3.6% in postmenopausal women at The Menopause Soc…

New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and strategic priorities

Dare Bioscience (NASDAQ: DARE - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Profitability This table compares Dare Bioscience and RYTHM's

New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%

View the video webcast here

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million

Video webcast now available  here

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript

Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA's 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**

President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here

National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation

SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company's common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a pr…

Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.45 per share a year ago.

Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July